Cue Biopharma, Inc. / Ascendant Health Sciences Ltd. (Ascendant-221)
2026 · Licensing/Option · $692M · Complete
Announcement Sentiment
71
Positive
Cue Biopharma (CUE) entered an exclusive global (ex-Greater China) license from Ascendant Health Sciences for Phase 2-stage anti-IgE antibody Ascendant-221 for $15M upfront plus up to $676.5M in development/regulatory/commercial milestones plus tiered royalties. Cue plans to initiate a global Phase 2b food-allergy trial after the China CSU readout in 2H 2026. UPDATE (Q1 2026 reporting): Cue has redesignated the in-licensed asset CUE-221 (formerly Ascendant-221); the China CSU Phase 2 readout remains expected in 2H 2026 and the global food-allergy Phase 2b remains gated on that data. Cue reported $16.4M cash at 3/31/2026 plus a subsequent $30M private placement and a $7.5M milestone receipt, funding milestones into 2026.